for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

ICON PLC

ICLR.OQ

Latest Trade

277.52USD

Change

0.39(+0.14%)

Volume

107,716

Today's Range

276.23

 - 

278.51

52 Week Range

168.90

 - 

294.64

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
277.13
Open
276.23
Volume
107,716
3M AVG Volume
12.02
Today's High
278.51
Today's Low
276.23
52 Week High
294.64
52 Week Low
168.90
Shares Out (MIL)
79.59
Market Cap (MIL)
22,056.44
Forward P/E
30.33
Dividend (Yield %)
--

Next Event

Q3 2021 ICON PLC Earnings Release

Latest Developments

More

Evergreen Therapeutics, Inc. Announces Agreement With Icon PLC To Conduct Phase II Clinical Trial For Covid-19 Drug Candidate

Icon To Acquire Pra Health Sciences

Cytocom Updates Investigational New Drug Application For Phase 2 Clinical Trial Of Cyto-205 For The Treatment Of Covid-19

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About ICON PLC

ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies. Its services include clinical trials management, biometric activities, consulting, imaging, contract staffing, informatics and laboratory services. The Company's information systems offerings include ICONIK, Firecrest, ADDPLAN, AptivAdvantage and Aptiv Insite. It conducts various laboratory tests on the patient's blood, urine and other bodily fluids at appropriate intervals during the trial. The Company offers clinical development services, including investigator recruitment, patient registries, outcomes research, clinical data management, immunoassay development and others.

Industry

Biotechnology & Drugs

Contact Info

South County Business Park, Dublin 18

00000

Ireland

+353.1.2912000

http://www.iconplc.com/

Executive Leadership

Ciaran Murray

Non-Executive Chairman of the Board

Stephen Cutler

Chief Executive Officer, Director

Brendan Brennan

Chief Financial Officer, Member of the Executive Committe

Diarmaid Cunningham

Executive Vice President, Chief Administrative Officer, General Counsel, Secretary

Ronan Murphy

Lead Independent Director

Key Stats

2.07 mean rating - 14 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

2.6K

2019

2.8K

2020

2.8K

2021(E)

5.4K
EPS (USD)

2018

6.090

2019

6.880

2020

6.530

2021(E)

9.162
Price To Earnings (TTM)
40.59
Price To Sales (TTM)
6.91
Price To Book (MRQ)
7.24
Price To Cash Flow (TTM)
50.86
Total Debt To Equity (MRQ)
17.26
LT Debt To Equity (MRQ)
17.26
Return on Investment (TTM)
17.51
Return on Equity (TTM)
11.33

Latest News

Latest News

Icon eyes growing virtual clinical trial market with $12 billion PRA Health deal

Icon Plc said on Wednesday it will buy rival PRA Health Sciences Inc in a deal valued at about $12 billion, to create a contract drug research firm that can tap into the growing demand for virtual clinical trials due to the pandemic.

BRIEF-Icon Acquires Medpass International

* ICON ACQUIRES MEDPASS INTERNATIONAL Source text for Eikon: Further company coverage:

BRIEF-Icon Reported Q4 Revenue Of $725.4 Mln Representing A 6.8% Year On Year Increase

* Q4 REPORTED REVENUE OF $725.4 MILLION REPRESENTING A 6.8% YEAR ON YEAR INCREASE OR 7.5% ON A CONSTANT CURRENCY BASIS

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up